

Anti-CD79B Antibody (Polatuzumab Biosimilar)

Cat. No. AB10


Description	
Reactivities	Human
Target	CD79B
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	48.9 kDa and 23.7 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
	CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.

Assay Data


Bis-Tris PAGE



Polatuzumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Polatuzumab Biosimilar is greater than 95% as determined by SEC-HPLC.

ELISA Data

Polatuzumab Biosimilar ELISA

0.1µg Human CD79B, His Tag Per Well



Immobilized Human CD79B, His Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Polatuzumab Biosimilar with the EC50 of 1.8ng/ml determined by ELISA.